Iambic Therapeutics vs Relay Therapeutics (2026)
Two clinical stage companies whose platforms attack the same limitation from different angles: that a static picture of a protein is a poor guide to whether a molecule will bind it. Relay built its whole thesis on motion, arguing that binding sites appear only in particular conformational states and that discovery anchored to fixed structures misses targets entirely, with multiple oncology programmes in humans and a public listing behind it. Iambic is physics informed in a different sense, with two named model families predicting protein ligand structure and cellular activity, its core method in peer review, released code, and a platform derived molecule with human data. Iambic is the more inspectable platform. Relay is the more advanced pipeline. Both should be judged on the molecules, because that is the only evidence that distinguishes a real platform from a good story.
- The core method is in peer review rather than in marketing, with two named model families doing the work, one for protein ligand structure prediction and one for predicting activity from molecular structure.
- It has a platform derived molecule with human data, which is the strongest evidence class available in this category and one few reach.
- Released code and publications give a partner something to evaluate technically rather than a demonstration to watch.
- The scientific thesis is the differentiator rather than the model: proteins move, binding sites appear only in particular conformational states, and a static structure approach misses targets that motion reveals.
- It is clinical stage with multiple oncology programmes in humans and listed on a public exchange, so both the pipeline and the finances are disclosed.
- The reciprocal design between computation and experiment is structural, with predictions tested and results feeding back rather than models running ahead of the laboratory.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Iambic Therapeutics and Relay Therapeutics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Iambic Therapeutics | Relay Therapeutics |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2020 | Not recorded |
| Headquarters | San Diego, California, United States | Cambridge, MA |
| Website | iambic.ai | relaytx.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Iambic Therapeutics its top capability grade on AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Relay Therapeutics, Iambic Therapeutics grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Relay Therapeutics on any axis it scores. Set against Iambic Therapeutics, Relay Therapeutics grades higher on Autonomy and Oversight Model, Security Certifications and Trust Center and Deployment Model and Data Residency. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Iambic Therapeutics or Relay Therapeutics?
On the axes where the AI Health Index separates them, Iambic Therapeutics grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence, and Relay Therapeutics grades higher on Autonomy and Oversight Model, Security Certifications and Trust Center and Deployment Model and Data Residency. Iambic Therapeutics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Iambic Therapeutics and Relay Therapeutics differ most?
The widest separation the AI Health Index records between Iambic Therapeutics and Relay Therapeutics is on Model and Technology Transparency, where Iambic Therapeutics grades A and Relay Therapeutics grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Iambic Therapeutics and Relay Therapeutics grade the same?
The AI Health Index grades Iambic Therapeutics and Relay Therapeutics the same on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Iambic Therapeutics and Relay Therapeutics not disclosed?
At the last review, at least one of Iambic Therapeutics and Relay Therapeutics published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both are clinical stage companies rather than software vendors, so a partner is buying a relationship and a pipeline rather than a tool, and the meaningful comparison is programmes in humans rather than platform description. Relay explains its scientific thesis clearly and its computational method not at all, which is the inverse of Iambic's position.
Neither publishes a security attestation, and neither needs the provider oriented axes in this index, which are scoping determinations rather than gaps. Judge both on assets that clear human trials, since every AI discovery platform looks convincing until the molecules meet patients.